Ted W. Johnson - Concepedia

Author

Ted W. Johnson

Also Known As

Johnson, T.W., Johnson, Ted W., M.A. McTigue, T Johnson, T. W. JOHNSON, T. W. Johnson, Ted Johnson, Ted W Johnson, Ted W. Johnson, Ted W. Johnson

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Harvard University Massachusetts General Hospital University of California, Los Angeles University of California San Diego

About

Ted W. Johnson is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	2.6K
2	Natural Sciences	8	8	332
3	Biochemistry	8	8	332
4	Engineering	4	4	104
5	Health Sciences	1	1	456

Ted W. Johnson

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations Ted W. Johnson, Paul Richardson, Simon Bailey, Journal of Medicinal Chemistry	2014	571
Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission Smruthi Karthikeyan, Joshua I. Levy, Peter De Hoff, Nature	2022	482
Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner, New England Journal of Medicine Oncogenic AgentMedicineGeneticsPharmacologyMolecular Biology	2015	479
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models Helen Y. Zou, Luc Friboulet, David P. Kodack, Cancer Cell Drug TargetHealth SciencesPreclinical ModelsMedicineRational Drug Design	2015	456
Using the Golden Triangle to optimize clearance and oral absorption Ted W. Johnson, Klaus Dress, Martin P. Edwards Bioorganic & Medicinal Chemistry Letters Golden TriangleMedicineOral CavityOral BiologyOral Medicine	2009	362
Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. James Leonard, Bernard Peers, Ted W. Johnson, Molecular Endocrinology Somatostatin Gene ExpressionImmunologySomatostatin PromoterPancreas TransplantationInsulin Signaling	1993	337
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke, Cancer Discovery	2018	298
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations Helen Y. Zou, Qiuhua Li, Lars D. Engstrom, Proceedings of the National Academy of Sciences Inhibitory ActivityRadiation OncologyFusion KinasesNovel TherapyCrizotinib-resistant Ros1 Mutations	2015	267
The Pancreatic Islet Factor STF-1 Binds Cooperatively with Pbx to a Regulatory Element in the Somatostatin Promoter: Importance of the FPWMK Motif and of the Homeodomain Bernard Peers, Seema Sharma, Ted W. Johnson, Molecular and Cellular Biology GeneticsMolecular GeneticsSomatostatin PromoterInsulin SignalingTranscriptional Regulation	1995	151
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Clinical Cancer Research	2021	132

Page 1